Canbridge Pharmaceuticals IncHKG 1228 Stock Report

CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing and currently employs 141 full-time employees. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.